Mereo BioPharma Group PLC ADR (MREO) - Total Liabilities
Based on the latest financial reports, Mereo BioPharma Group PLC ADR (MREO) has total liabilities worth $6.56 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mereo BioPharma Group PLC ADR - Total Liabilities Trend (2015–2025)
This chart illustrates how Mereo BioPharma Group PLC ADR's total liabilities have evolved over time, based on quarterly financial data. See MREO working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Mereo BioPharma Group PLC ADR Competitors by Total Liabilities
The table below lists competitors of Mereo BioPharma Group PLC ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Joong Ang Enervis Co. Ltd
KQ:000440
|
Korea | ₩4.64 Billion |
|
Heidelberger Beteiligungsholding AG
F:IPOK
|
Germany | €276.00K |
|
Mangalam Organics Limited
NSE:MANORG
|
India | Rs4.21 Billion |
|
Donkeyrepublic Holding AS
CO:DONKEY
|
Denmark | Dkr97.34 Million |
|
Thai Solar Energy Public Company Limited
BK:TSE
|
Thailand | ฿3.91 Billion |
|
Pharmx Technologies Ltd
AU:PHX
|
Australia | AU$2.90 Million |
|
Promateris SA
RO:PPL
|
Romania | RON94.57 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Mereo BioPharma Group PLC ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MREO market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mereo BioPharma Group PLC ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mereo BioPharma Group PLC ADR (2015–2025)
The table below shows the annual total liabilities of Mereo BioPharma Group PLC ADR from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $5.00 Million | -67.57% |
| 2024-12-31 | $15.42 Million | -3.39% |
| 2023-12-31 | $15.96 Million | -38.63% |
| 2022-12-31 | $26.01 Million | -49.93% |
| 2021-12-31 | $51.95 Million | -51.25% |
| 2020-12-31 | $106.55 Million | +74.13% |
| 2019-12-31 | $61.19 Million | +77.34% |
| 2018-12-31 | $34.51 Million | +1.93% |
| 2017-12-31 | $33.85 Million | +350.87% |
| 2016-12-31 | $7.51 Million | +30.42% |
| 2015-12-31 | $5.76 Million | -- |
About Mereo BioPharma Group PLC ADR
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navi… Read more